Cover Image
市場調查報告書

威爾森氏症的全球市場:產業分析與未來展望

Global Wilson's Disease Market: Industry Analysis & Outlook 2016-2020

出版商 Koncept Analytics 商品編碼 367890
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
威爾森氏症的全球市場:產業分析與未來展望 Global Wilson's Disease Market: Industry Analysis & Outlook 2016-2020
出版日期: 2016年08月23日 內容資訊: 英文 45 Pages
簡介

本報告提供全球威爾森氏症的相關市場相關分析,疾病概要和目前的主要治療方法、治療藥,世界市場趨勢預測 - 患者數及治療藥的市場規模的預測值 -、主要市場 (歐洲、美國)的詳細趨勢,主要的推動及阻礙市場要素,主要企業簡介和業績評估的資訊彙整,為您概述為以下內容。

第1章 市場概要

  • 簡介
  • 病因
  • 症狀 (肝臟、神經系統、眼等)
  • 診斷
  • 醫藥品的治療
    • D-penicillamine
    • torienchin
    • 鋅鹽
    • Bis-Choline Tetrathiomolybdate - Decuprate

第2章 全球市場

  • 全球孤兒藥市場收益額:成果值
  • 全球孤兒藥市場收益額:預測值
  • 威爾森氏症的患病人數:各地區
  • 威爾森氏症的市場規模:各治療法 - 新患者的情況
  • 威爾森氏症的市場規模:各治療法 - 既往患者的情況
  • Decuprate的市場收益額 (全球):預測值
  • 肝臟移植手術的實施數量:各地區

第3章 各地區市場

  • 歐洲
    • 威爾森氏症的患病人數 (預測值)
    • 威爾森氏症的市場規模:各治療法
    • 以鋅治療的威爾森氏症的患者數 (預測值)
    • 螯合劑治療的威爾森氏症的患者數 (預測值)
    • Decuprate治療的威爾森氏症的患者數 (預測值)
  • 美國
    • 威爾森氏症的患病人數 (預測值)
    • 威爾森氏症的市場規模:各治療法
    • 以鋅治療的威爾森氏症的患者數 (預測值)
    • 螯合劑治療的威爾森氏症的患者數 (預測值)
    • 螯合劑的市場收益額 (成果值)
    • 螯合劑的市場收益額 (預測值)
    • Decuprate治療的威爾森氏症的患者數 (預測值)

第4章 市場動態

  • 市場成長的推動要素
  • 市場趨勢
  • 市場課題

第5章 競爭環境

  • 企業間競爭:市場收益額
  • 企業間競爭:市值
  • 企業間競爭:收益率

第6章 企業簡介

  • Valeant Pharmaceuticals Inc.
  • Meda AB
  • Teva Pharmaceuticals
  • Wilson Therapeutics

圖表一覽

目錄

Wilson's disease is a rare disease and is named after Kinnear Wilson who was the first to describe this disorder in 1912. His description terms the disease as a "progressive lenticular degeneration," a hereditary, fatal neurological disease that is usually accompanied by chronic liver ailment that leads to a condition called cirrhosis. Wilson's disease is a hereditary disorder that leads to unwarranted accumulation of copper in crucial organs such as the liver, brain etc. The patient starts to accumulate copper from birth but diagnosis tends not to occur only in the later ages. The primary signs of Wilson's disease become prominent usually between the ages of 12 and 23 years.

Wilson's disease is caused by the mutation of a gene named ATP7B. Absent or reduced function of ATP7B protein leads to reduced elimination of copper into the bile. Wilson's disease is inherited as an autosomal recessive trait, which means that in order to develop the disease one must inherit two procreations of the defective gene, one from each parent. If a person receives only one abnormal gene from either of the parents, he/she is not likely to get affected by the Wilson's disease. Wilson's disease may be difficult to primarily diagnose as the symptoms are alike to other health issues like heavy metal poisoning, hepatitis C, and cerebral palsy.

The important factors that are anticipated to drive the market include rising prices of chelators in the US, rising attractiveness of orphan drugs market, increasing global healthcare expenditure as well as spending on medicines. The noteworthy trends in the market include falling number of prescriptions for Wilson's disease, and the development of gene therapy as a potential cure for the disease. However, the market is confronted by crucial challenges such as under-diagnosis of the disease, lack of safety in treatments, poor compliance to current treatments and unmet efficacy needs.

This report provides a wide-ranging study of global Wilson's disease market and also its key regional markets such as the US and Europe. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global Wilson's disease industry is highly competitive consisting of several large corporations. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

Table of Contents

1. Market Overview

  • 1.1 Introduction
  • 1.2 Causes
  • 1.3 Symptoms
    • 1.3.1 Hepatic Symptoms
    • 1.3.2 Neurological Symptoms
    • 1.3.3 Ophthalmic Symptoms
    • 1.3.4 Other Symptoms
  • 1.4 Diagnosis
  • 1.5 Treatment through Medications
    • 1.5.1 D-penicillamine
    • 1.5.2 Trientine
    • 1.5.3 Zinc Salts
    • 1.5.4 Ammonium tetrathiomolybdate
    • 1.5.5 Bis-Choline Tetrathiomolybdate - Decuprate

2. Global Market

  • 2.1 Global Orphan Drugs Market Revenue - Actuals
  • 2.2 Global Orphan Drugs Market Revenue - Forecast
  • 2.3 Wilson's Disease Prevalence by Region
  • 2.4 Wilson's Disease Market by Treatment - New Patients
  • 2.5 Wilson's Disease Market by Treatment - Experienced Patients
  • 2.6 Global Decuprate Revenue - Forecast
  • 2.7 Global Liver Transplantation by Region

3. Regional Markets

  • 3.1 Europe
    • 3.1.1 Wilson's Disease Prevalence - Forecast
    • 3.1.2 Wilson's Disease Market by Treatment
    • 3.1.3 Wilson's Disease Patients Treated with Zinc - Forecast
    • 3.1.4 Wilson's Disease Patients Treated with Chelators - Forecast
    • 3.1.5 Wilson's Disease Patients Treated with Decuprate - Forecast
  • 3.2 The US
    • 3.2.1 Wilson's Disease Prevalence - Forecast
    • 3.2.2 Wilson's Disease Market by Treatment
    • 3.2.3 Wilson's Disease Patients Treated with Zinc - Forecast
    • 3.2.4 Wilson's Disease Patients Treated with Chelators - Forecast
    • 3.2.5 Chelators Market Revenue - Actuals
    • 3.2.6 Chelators Market Revenue - Forecast
    • 3.2.7 Wilson's Disease Patient Treated with Decuprate - Forecast

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Rising Prices of Chelators in the US
    • 4.1.2 Rising Attractiveness of Orphan Drug Market
    • 4.1.3 Rising Global Spending on Medicines
    • 4.1.4 Increasing Healthcare Expenditure
  • 4.2 Trends
    • 4.2.1 Falling Number of Prescription for Chelators
    • 4.2.2 Gene Therapy for Wilson's Disease
  • 4.3 Challenges
    • 4.3.1 Under-Diagnosis of the Disease
    • 4.3.2 Lack of Safety in Treatments
    • 4.3.3 Poor Compliance of Patients to Current Treatments
    • 4.3.4 Unmet Efficacy Needs

5. Competitive Landscape

  • 5.1 Competition by Revenue
  • 5.2 Competition by Market Capitalization
  • 5.3 Competition by Profitability

6. Company Profiles

  • 6.1 Valeant Pharmaceuticals Inc.
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Meda AB
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Teva Pharmaceuticals
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Wilson Therapeutics
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies

List of Charts

  • Global Orphan Drugs Market Revenue - Actuals (2012-2015)
  • Global Orphan Drugs Market Revenue - Forecast (2016-2020)
  • Wilson's Disease Prevalence by Region (2015)
  • Wilson's Disease Market by Treatment - New Patients (2015)
  • Wilson's Disease Market by Treatment - Experienced Patients (2015)
  • Global Decuprate Revenue - Forecast (2020-2025)
  • Global Liver Transplantation by Region (2015)
  • Wilson's Disease Prevalence - Forecast (2015-2020)
  • Wilson's Disease Market by Treatment (2015)
  • Wilson's Disease Patients Treated with Zinc - Forecast (2015-2020)
  • Wilson's Disease Patients Treated with Chelators - Forecast (2015-2020)
  • Wilson's Disease Patients Treated with Decuprate - Forecast (2020-2025)
  • Wilson's Disease Prevalence - Forecast (2015-2020)
  • Wilson's Disease Market by Treatment (2015)
  • Wilson's Disease Patients Treated with Zinc - Forecast (2015-2020)
  • Wilson's Disease Patients Treated with Chelators - Forecast (2015-2020)
  • Chelators Market Revenue - Actuals (2012-2015)
  • Chelators Market Revenue - Forecast (2016-2020)
  • Wilson's Disease Patient Treated with Decuprate - Forecast (2020-2025)
  • Average Price of Chelators in the US (2012-2015)
  • Median Cost of Phase III Trials (2015)
  • Global Spending on Medicines (2010-2015)
  • Global Healthcare Expenditure Per Capita (2011-2015)
  • Number of Prescriptions for Chelators in the US (2011-2015)
  • Revenue Comparison of Key Players (2015)
  • Market Capitalization Comparison of Key Players (2015)
  • Net Profit Margin Comparison of Key Players (2015)
  • Revenue Share by Business Segments, Valeant Pharmaceuticals (2015)
  • Revenue and Net Income, Valeant Pharmaceuticals (2013-2015)
  • Revenue Share by Business Segments, Meda AB (2015)
  • Revenue and Net Income, Meda AB (2014-2015)
  • Revenue Share by Business Segments, Teva Pharmaceuticals (2015)
  • Revenue and Net Income, Teva Pharmaceuticals (2013-2015)
  • Revenue and Net Income, Wilson Therapeutics (2013-2015)
Back to Top